Ultragenyx Pharma (RARE) Misses Q2 EPS by 20c

Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($0.83), $0.20 worse than the analyst estimate of ($0.63).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• On Holding AG (ONON) Stock: Market Doesn't Appreciate Brand's Potential, Says Analyst
• Cintas Corp. (CTAS) Tops Q1 EPS by 1c, Offers Guidance